More than 10k cans of Coca-Cola voluntarily recalled over possible plastic contamination
More than 10,000 cans of Original Coca-Cola have been voluntarily recalled due to possible plastic contamination.
The recall was initiated by Coca-Cola manufacturer Reyes Coca-Cola Bottling on March 6 and was officially designated a Class II recall by the U.S. Food and Drug Administration on March 24, according to an FDA report.
According to the FDA, the Class II designation indicates that use of a recalled product could cause temporary or reversible health effects or that the probability of "serious adverse health consequences" is "remote."
In total, 864 12-count packs of Coco-Cola Original Taste cans are affected.
The recall only affects specific 12-ounce Coca-Cola Original cans produced by Reyes Coca-Cola Bottling, LLC in Milwaukee, Wisconsin. Only certain batches distributed in Illinois and Wisconsin are included.
Recall on Diet Coke, Fanta Orange and Sprite due to possible contamination
To check if your Coca-Cola is part of the recall, look for the following details on the can or packaging:
Can UPC: 0 49000-00634 6
Pack UPC: 0 49000-02890 4
Date code: Sept. 29, 2025 (SEP2925MDA)
Time stamp: 1100-1253
Labeling: "Canned Under Authority of the Coca-Cola Company, Atlanta, GA 30313."
Reached for comment Tuesday, Coca-Cola referred ABC News to Reyes Coca-Cola Bottling. In a statement, a spokesperson for the bottling company confirmed the voluntary recall.
"The cases are being withdrawn because they did not meet our high-quality standards," the spokesperson said. "We are taking this voluntary action because nothing is more important to us than providing high-quality products to the people who drink our beverages."
More than 10k cans of Coca-Cola voluntarily recalled over possible plastic contamination originally appeared on goodmorningamerica.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The Smartest Growth Stock to Buy With $1,000 Right Now
Consumer staples makers have long been able to grow their businesses through good and bad economic times. Some of the best consumer staples stocks are Dividend Kings. One consumer staple Dividend King has a good yield and attractive valuation. 10 stocks we like better than Coca-Cola › Quick, think about soda companies. What brand comes to mind? Probably Coca-Cola (NYSE: KO). That makes sense, given that Coca-Cola is one of the largest and best-known consumer staples brands in the world. But is it the smartest growth stock to buy if you have $1,000 to invest right now? Don't hit the buy button until you read about this high-yield alternative. From a big-picture perspective, Coca-Cola makes food, even though its products get their own category with the consumer staples space. Beverages are still a life necessity, even if its eponymous product is more for pleasure than need. The company is an industry powerhouse. Not only is Coke one of the best known, and most beloved, beverage brands, but Coca-Cola happens to have a massive distribution network, impressive marketing skills, and powerful research and development chops. The company's scale, meanwhile, gives it the wherewithal to act as an industry consolidator, buying up smaller brands and beverage concepts to round out its product portfolio. That, in turn, helps to keep Coca-Cola's brands relevant with consumers. The company's business is so strong that it has been a longtime holding of Warren Buffett within Berkshire Hathaway's stock portfolio. If Buffett has put billions into Coca-Cola, why shouldn't you put in $1,000? There's one notable reason: Investors have fully priced Coca-Cola's shares. The stock's price-to-sales ratio and its price-to-earnings ratio are both above their five-year averages, and the dividend yield is near 10-year lows. The business is doing relatively well right now, but virtually everyone seems to know it. One of the other factors that sets Coca-Cola apart is its status as a Dividend King. But it isn't the only Dividend King beverage company. Direct competitor PepsiCo (NASDAQ: PEP) has increased its dividend annually for 53 years and counting. Meanwhile, PepsiCo's price-to-sales and price-to-earnings ratios are below their five-year averages, and its yield is toward the high end of its historical range. So, unlike Coca-Cola, PepsiCo looks cheap. PepsiCo stands out on the valuation front, but it also stands out on the diversification front. Like Coca-Cola, it has a globally diversified business. But PepsiCo operates in the salty snack and packaged foods spaces, too. That gives it more levers to pull to support long-term growth and more businesses to lean on when one of its divisions is facing difficulty. And make no mistake, every company, no matter how good, eventually faces hard times. The best companies, which include Dividend Kings, are the ones that successfully manage through the hard times. While Coca-Cola is performing quite well today, PepsiCo isn't. That's why its yield is a historically high 4.3% and its stock price has lost a third of its value since early 2023. But PepsiCo isn't giving up. In fact, it is leaning on its successful playbook and buying smaller brands (Siete and Poppi) that are more relevant with consumers right now. That should, in time, help PepsiCo to get back on the growth track. If you're looking at Coca-Cola today, you should probably give PepsiCo a closer look. But don't just think about how each business is performing this very second. Think about their valuations in relation to their performance and, just as important, what each company is doing to ensure they succeed. They both have solid businesses and are working on a bright future, but PepsiCo isn't getting any credit for it because it is facing some near-term headwinds. If you can think long term, putting $1,000 into PepsiCo today could end up being a huge win for your future wealth. Note that one of the keys to Buffett's investment approach is buying good companies when they look attractively priced. Between Coca-Cola and PepsiCo, it is PepsiCo that passes that simple screen. Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in PepsiCo. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool has a disclosure policy. The Smartest Growth Stock to Buy With $1,000 Right Now was originally published by The Motley Fool
New York Post
4 hours ago
- New York Post
Lab-grown salmon is now FDA approved — here's why this one restaurant is putting it on the menu
Land ho! You've heard of fresh-caught salmon and even farm-raised — but what about lab-grown? San Francisco cellular agriculture company Wildtype is the latest company to get FDA approval for its lab-grown salmon Only three other companies have gotten the stamp of approval to sell cultivated salmon so far. The company made waves in the food and culinary sectors after announcing that its hero product, saku salmon, got approved in 'a thorough pre-market safety consultation.' Curious people can find the fish on the menu at Portland, Oregon, restaurant Kann — a James Beard award-winning Haitian spot by chef Gregory Gourdet. For June, the cultured salmon will only grace the menu every Thursday night, but in July, it is slated to be a nightly offering. 'Our saku is sushi-grade and best served raw in dishes like sushi, crudo, and ceviche,' Wildtype explains on its website. 'We made it for world-class chefs who seek out the distinct flavor and freshness of raw seafood.' And according to the FDA, they view lab-grown salmon 'as safe as comparable foods produced by other methods,' the FDA wrote in its public response letter. The FDA's only gripe with Wildtype's cultivated salmon so far is that the company refers to it as 'cultured salmon cell material' — which is not 'our recommendation of that term as an appropriate common or usual name for declaring the substance in accordance with FDA's labeling requirements,' the agency said. This interest in lab-grown salmon is due to both wild-caught and farm-raised versions containing levels of mercury. Wild-caught salmon is also susceptible to picking up chemicals in local waters. So, how exactly is lab-grown salmon made? The process can be broken down into three steps: source, grow and harvest. Living cells from Pacific salmon are taken from fish and then placed into cell cultivators that mimic the temperature, pH, and nutrients of a wild fish — allowing the cells to grow, as explained by Wildtype. Once fully matured and harvested, the living 'salmon cells' are fused with plant-based ingredients that imitate the texture and appearance of true salmon. Experts warn that typically, both wild-caught and farm-raised salmon contain traceable levels of mercury and are susceptible to picking up chemicals in local waters. Oran Tantapakul – By producing synthetic seafood, Wildtype says it aims to 'sustainably meet the food security challenges of this century' and minimize the damaging environmental implications of farming and fishing practices, while reducing 'exposure to common contaminants we'd rather avoid.' According to the Washington State Department of Health, farmed salmon can sometimes be exposed to organic contaminants and pests like sea lice more often than wild-caught salmon, but rest assured: 'most of the salmon available for us to eat is farmed,' the agency says. Synthetic salmon hasn't hit the grocery store shelves just yet but given cultural interest in plant-based, meatless, and lab-grown products — that day seems to be just around the corner.
Yahoo
6 hours ago
- Yahoo
Opinion - Trump shouldn't import socialist price controls
Remember when Republican presidential candidate Donald Trump castigated 'Comrade Kamala' Harris, then the Democratic nominee, for supporting price controls? It wasn't that long ago — just last August. At a campaign rally in Pennsylvania, Trump told the crowd: 'In her speech yesterday, Kamala went full Communist … She wants to destroy our country. After causing catastrophic inflation, Comrade Kamala announced that she wants to institute socialist price controls.' Harris's price controls were largely aimed at food in grocery stores, though she also frequently touted the 2022 Inflation Reduction Act's backdoor price controls — under the guise of 'negotiations' — on a certain number of expensive drugs. Trump was right to criticize Harris for supporting price controls on food, as well as prescription drugs. And, given the election results, it seems the public agreed with him. Price controls are the progressive left's go-to solution for almost all economic problems. But price controls virtually always lead to unintended consequences: shortages of the price-controlled products or services; lower quality as manufacturers cut corners to meet government-imposed price points; less innovation, since companies don't know if they'll be allowed to recover their costs; and a black market where people pay more to get what they want or need. So it's puzzling to see Trump now proposing a version of drug price controls himself. It's not the first time, either. During his first term, Trump pushed for 'drug importation,' encouraging U.S. citizens to buy medicines from countries like Canada — even though the FDA has warned those drugs could be fake or substandard. The effort fizzled, and even Florida, which tried a state-level importation scheme, eventually abandoned its program. Trump's latest idea is called 'Most Favored Nation' pricing. Details are thin, but a recent executive order says, 'To the extent consistent with law, the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' That 'most-favored' country will almost certainly be one with government-run health care — that is, socialized medicine. These systems are known for price controls, which lead to shortages, long wait times, and limited access to cutting-edge treatments. The goal of Most Favored Nation is to lower prices on expensive drugs. Americans do pay more for brand-name drugs than patients elsewhere. But they also pay less for generics, which account for roughly 90 percent of all prescriptions. One reason for the disparity is the middlemen in our system, known as pharmacy benefit managers. Their job is to negotiate lower prices with drugmakers. But those savings often don't make it to patients. Instead, pharmacy benefit managers keep a big chunk for themselves — on average, $0.42 of every $1 spent on brand-name drugs in the commercial market, by one estimate. In many cases, those pharmacy benefit manager cuts are larger than the total price of the drug in Europe. It's clear our system could work better. 'Shark Tank' entrepreneur Mark Cuban launched the Cost Plus Drug Company in 2022 to bypass these middlemen. The Cost Plus website says, 'Our prices are the true cost to get each medication from the manufacturer to you. We cut out the pharmacy middlemen and negotiate directly with manufacturers to get the best possible price.' The company tacks on 15 percent for overhead and a $5 filling fee. While customers may not save much on some widely used generics, the discounted prices on more expensive brand name and generic drugs are significantly lower than what most people would experience at their local pharmacy. Cost Plus has hundreds of drugs for nearly 100 listed medical conditions, and it's looking to add new drugs all the time. It's only been in business a few years and is working to expand. We also shouldn't ignore the fact that Americans are subsidizing below-market prices abroad. The United States funds a disproportionate share of global pharmaceutical innovation, while other wealthy nations impose price caps and benefit from our investment. If Trump wants to stop other countries from taking advantage of us, he should take the approach he's using to get countries to pay more for defense. Cuban's Cost Plus experiment proves we don't need Most Favored Nation pricing. Let socialized systems keep their socialized prices, limited access and denial of care. Tweaking a line Trump likes to use and applying it to prescription drugs: We don't need a new law. We just don't need a middleman. Merrill Matthews is a public policy and political analyst and the co-author of 'On the Edge: America Faces the Entitlements Cliff.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
